Adiponectin as a biomarker in liver cirrhosis-A systematic review and meta-analysis.

ABSTRACT:

Introduction

Adiponectin, a key adipokine, shows promise as a non-invasive biomarker for liver cirrhosis by reflecting inflammation and metabolic changes, but conflicting findings highlight the need for a systematic review and meta-analysis to clarify its role. Our study aimed to evaluate adiponectin levels across various stages of liver cirrhosis, compare them with other chronic liver diseases (CLD) and hepatocellular carcinoma (HCC), and assess its potential as a diagnostic and prognostic biomarker.

Methods

Our systematic search was conducted on September 2023 using PubMed, EMBASE and Scopus, searching for observational studies evaluating serum and plasma adiponectin levels in liver cirrhosis. Inclusion and exclusion criteria were applied, and study quality was assessed us

SUBMITTER: Ismaiel A 

PROVIDER: S-EPMC11628646 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature